Mike Gorenstein

Cronos group CEO Mike Gorenstein (NASDAQ:CRON) says the cannabis industry should not rely solely on Democratic leadership for reform. Instead, he says President-elect Donald Trump is personally more open to cannabis reform than Biden, but warned against expecting rapid changes, as cannabis won...

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced its 2024 third-quarter business results on Tuesday. "Our results this quarter demonstrate that our long-term strategy is working," said Mike Gorenstein, chairman, president and CEO. "With record net revenue and a disciplined approach to operating...

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced on Tuesday its 2024 second-quarter business results. The company reported $27.8 million in net revenue during the quarter, representing a 46% year-over-year increase. Mike Gorenstein, chairman, president and CEO of Cronos, said that's the "...

Cronos Group Inc.'s (NASDAQ:CRON) (TSX:CRON) Spinach brand is expanding its portfolio of cannabis products just in time for the summer months. The Toronto-based company unveiled new flavors and formats from its SOURZ by Spinach edibles and a premier milled flower product. The new SOURZ by Spinach...

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced on Thursday the expansion of Cronos Growing Company, a cannabis cultivation business of which the Toronto-based company owns 50%. What Happened The investment will be funded by a roughly $51 million (CA$70 million) secured non-revolving credit...

Cronos Group Inc., (NASDAQ: CRON) a global cannabinoid company, has reported an increase in net revenue for the first quarter of 2024. The company's net revenue surged by 30%, reaching $25.3 million, driven primarily by sales in Canada and Israel. Despite this revenue upswing, Cronos posted a...

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced on Tuesday that it's expanding its medical brand, PEACE NATURALS, into the United Kingdom with its first shipment of cannabis flower to GROW Pharma. The Toronto-based cannabis company has partnered with a distributor of prescribed medicinal...

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) released its 2023 fourth quarter and full-year business results Thursday with quarterly revenue of $23.9 million, up by $1.9 million from the same quarter of 2022. "In 2023, we significantly improved our cash flow from operations driven primarily by...

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced on Tuesday that it is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited. The Toronto-based company owns roughly 10% of Vitura's common shares, formerly known as Cronos Australia...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced on Monday that its wholly-owned subsidiary entered into an agreement with Future Farmco Canada Inc., a vertical farming company, for the sale and leaseback of its Ontario, Cananda-based property. What Happened Under the deal, Future...

As the top US cannabis market, California is witnessing an influx of THCV products, some of the top-selling Canadian provinces are getting in on it, too. Toronto-based Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced Monday the launch of two new THCV-infused products - Spinach FEELZ Full Tilt...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) is exiting its existing U.S. hemp-derived CBD-focused operations by the end of the second quarter of 2023. The company noted it has made this decision to improve its cash flow in the near term and position itself to directly enter the...

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON), released its 2023 first quarter business results, revealing net revenue of $20.1 million, a decrease of 19.5% compared to $25 million in Q1 2022. Q1 2023 Financial Highlights Gross profit of $2.4 million in Q1 2023, a decrease of 65.6% compared to $6.9...

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) in honor of Earth Day, released a Sustainability Study, which outlines the benefits of using fermentation manufacturing methods for cannabinoid production over the impact of traditional methods of cannabis extraction, which leverage indoor cultivation...

The past 12 months have been a wild ride for both investors and cannabis shareholders, as evidenced by big rallies as well as steep declines. Cannabis stocks substantially fell over the last year, with the U.S. Marijuana Index plunging 70% in 2022, according to BNN Bloomberg. Analysts and market...